


Window of opportunity study of preoperative immunotherapy with atezolizumab (Tecentriq®) or FAP-interleukin 2v (IL2v) (RO6874281) in local squamous cell carcinoma of the head and neck- PIONEER



SCCHN: squamous cell carcinoma of the head and neck